PMC7572681_01
fundus picture and FFA findings of case 1: (A,B) RE posterior pole showing AS with comet-tail lesions, no macular leakage in arteriovenous phase; (C) LE posterior pole fundus pic showing AS with CNV with surrounding retinal haemorrhage; (D,E,F) RE early, mid and late phase FFA showing the extent of CNV with leakage
PAMJ-36-294-g001.jpg
PMC7572681_01_PAMJ-36-294-g001.jpg
F1
LE macula showed an early hyperfluorescent lesion roughly 1.5DD (disc diameter) with surrounding blocked fluorescence in the early phase, followed by increasing hyperfluorescence in the mid-phase and leakage in the late phase (Figure 1).
SD-OCT images of three cases; (A,B,C) case 1 showing CME with SRF with type II CNV at presentation, resolving SRF with FVPED at 1 month, resolved SRF with FVPED and foveal thinning at the 3rd month post ranibizumab injections; (D,E,F) case 2 showing small type II CNV with SRF at presentation, decreasing SRF at 1 month and resolved SRF at month 3 post ranibizumab injections; (G,H,I) case 3 showing a large subretinal hyperreflective membrane (SHRM) with SRF at presentation, resolved SRF at 1 month, no SRF and early outer retinal tubule formation at the nasal edge of SHRM at the 3rd month post aflibercept injections
PAMJ-36-294-g002.jpg
PMC7572681_03_PAMJ-36-294-g002.jpg
F2
Post 3 consecutive monthly doses of intravitreal aflibercept injection, SRF resolved, CMT improved to 270mum and BCVA recovered to 20/30 (Figure 2 G,H,I).
PMC7572681_02
SD-OCT images of three cases; (A,B,C) case 1 showing CME with SRF with type II CNV at presentation, resolving SRF with FVPED at 1 month, resolved SRF with FVPED and foveal thinning at the 3rd month post ranibizumab injections; (D,E,F) case 2 showing small type II CNV with SRF at presentation, decreasing SRF at 1 month and resolved SRF at month 3 post ranibizumab injections; (G,H,I) case 3 showing a large subretinal hyperreflective membrane (SHRM) with SRF at presentation, resolved SRF at 1 month, no SRF and early outer retinal tubule formation at the nasal edge of SHRM at the 3rd month post aflibercept injections
PAMJ-36-294-g002.jpg
PMC7572681_03_PAMJ-36-294-g002.jpg
F2
Post 3 consecutive monthly doses of intravitreal aflibercept injection, SRF resolved, CMT improved to 270mum and BCVA recovered to 20/30 (Figure 2 G,H,I).
fundus picture and FFA findings of case 2: (A,B,C) RE posterior pole shows AS with disciform scar in macula, multiple comet-tail lesions inferiorly and staining on late phase FFA; (D,E,F) LE posterior pole shows AS with streaks across macula, early and late phase FFA showing staining of the streaks with CNV leakage
PAMJ-36-294-g003.jpg
PMC7572681_02_PAMJ-36-294-g003.jpg
F3
FFA showed LE early hyperfluoresence with mid phase leak corresponding to CNV and RE staining of the macular scar (Figure 3).
PMC7572681_03
SD-OCT images of three cases; (A,B,C) case 1 showing CME with SRF with type II CNV at presentation, resolving SRF with FVPED at 1 month, resolved SRF with FVPED and foveal thinning at the 3rd month post ranibizumab injections; (D,E,F) case 2 showing small type II CNV with SRF at presentation, decreasing SRF at 1 month and resolved SRF at month 3 post ranibizumab injections; (G,H,I) case 3 showing a large subretinal hyperreflective membrane (SHRM) with SRF at presentation, resolved SRF at 1 month, no SRF and early outer retinal tubule formation at the nasal edge of SHRM at the 3rd month post aflibercept injections
PAMJ-36-294-g002.jpg
PMC7572681_03_PAMJ-36-294-g002.jpg
F2
Post 3 consecutive monthly doses of intravitreal aflibercept injection, SRF resolved, CMT improved to 270mum and BCVA recovered to 20/30 (Figure 2 G,H,I).
fundus picture and FFA findings of case 3: (A,B) RE posterior pole shows AS, comet-tail lesions in mid peripheral retina; (C) and no macular leakage on FFA; (D,E,F) LE posterior pole shows AS with subretinal hyperreflective membrane in macula, early and mid phase FFA showing leakage from the CNV complex
PAMJ-36-294-g004.jpg
PMC7572681_03_PAMJ-36-294-g004.jpg
F4
FFA showed in LE early hyperfluorescence with mid phase leakage (Figure 4).